Abstract
Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Current Molecular Medicine
Title: Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?
Volume: 11 Issue: 9
Author(s): M. Mariani, S. Shahabi, S. Sieber, G. Scambia and C. Ferlini
Affiliation:
Keywords: Tubulin, biomarkers, drug-resistance, poor outcome, pharmacogenomics, toxicity, biomediators, myeloid leukemia, tumors, imatinib, dasatinib, nilotinib, oncogene, carcinoma, angiogenesis
Abstract: Class III β-tubulin (TUBB3) is a prominent mechanism of drug resistance expressed in a variety of solid tumors and particularly in lung and ovarian cancer. In the classical view, TUBB3 expression and drug resistance have been linked, and together they have been associated with a perturbation in microtubule dynamics. In keeping with this observation, TUBB3 was associated with drug resistance only when chemotherapy included a taxane in its chemical composition. In this review, we demonstrate that the classical supposition about TUBB3 is not correct, and that instead TUBB3 expression is linked to drug resistance as a complex survival mechanism activated by microenvironmental conditions such as poor nutrient supply and hypoxia.
Export Options
About this article
Cite this article as:
Mariani M., Shahabi S., Sieber S., Scambia G. and Ferlini C., Class III β -Tubulin (TUBB3): More than a Biomarker in Solid Tumors?, Current Molecular Medicine 2011; 11 (9) . https://dx.doi.org/10.2174/156652411798062368
DOI https://dx.doi.org/10.2174/156652411798062368 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Contemporary Progress in the Synthesis and Reaction of 2-Arylbenzothiazole: A Review
Current Organic Chemistry Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Strategies to Improve the Killing of Tumors Using Temozolomide: Targeting the DNA Repair Protein MGMT
Current Medicinal Chemistry Regulation of Expression and Function of IDO in Human Dendritic Cells
Current Medicinal Chemistry αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology
Current Topics in Medicinal Chemistry Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Functional and Molecular Ultrasound Imaging: Concepts and Contrast Agents
Current Medicinal Chemistry FAK and p53 Protein Interactions
Anti-Cancer Agents in Medicinal Chemistry Non-Classical Structures Among Current Platinum Complexes with Potential as Antitumor Drugs
Current Topics in Medicinal Chemistry Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advancements in 1,4-Disubstituted 1H-1,2,3-Triazoles as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry A Disposable, Highly Sensitive Biosensing System: Determination of Haptoglobin as a Significant Acute Phase Biomarker
Current Analytical Chemistry Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Scheduling of Taxanes: A Review
Current Clinical Pharmacology Recent Advances in Radiopharmaceutical Application of Matched-Pair Radiometals
Current Topics in Medicinal Chemistry Prophylaxis of Cancer
Current Cancer Therapy Reviews Cardiac Toxicities of Antiangiogenic Therapies
Current Angiogenesis (Discontinued)